ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
-1.03%
Bitcoin
62,751.52
6.14%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. SAB Biotherapeutics Inc (SABS)

  7. SAB Biotherapeutics Inc (SABS) Noticias

SABS SAB Biotherapeutics Inc

4.03
0.01 (0.25%)
Fuera de horario
Última actualización: 16:07:01
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
SAB Biotherapeutics Inc SABS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.01 0.25% 4.03 16:07:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.00 4.00 4.1002 4.03 4.02
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
16/4/202406:15GLOBESAB Biotherapeutics Provides SAB-142 Trial Update
08/4/202406:15GLOBESAB Biotherapeutics to Present at INNODIA Annual Meeting
04/4/202406:15GLOBESAB Biotherapeutics to Present at the Needham Virtual..
29/3/202406:15GLOBESAB Biotherapeutics Reports Full Year 2023 Operating and..
25/3/202409:15GLOBESAB Biotherapeutics Announces Clinical Partnership with..
08/3/202415:30EDGAR2Form 8-K - Current report
23/2/202415:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202415:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202407:00GLOBESAB Biotherapeutics to Present at the BIO CEO & Investor..
08/2/202407:00GLOBESAB Biotherapeutics to Present at the Oppenheimer..
02/2/202406:53EDGAR2Form 8-K - Current report
02/2/202406:30GLOBESAB Biotherapeutics Announces Executive Leadership Change
26/1/202415:15EDGAR2Form 8-K - Current report
26/1/202415:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
25/1/202416:00EDGAR2Form 8-K - Current report
23/1/202416:58GLOBESAB Biotherapeutics Regains Compliance with Nasdaq Minimum..
19/1/202415:21EDGAR2Form 8-K - Current report
03/1/202408:00EDGAR2Form 8-K - Current report
02/1/202415:30GLOBESAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
18/12/202308:34EDGAR2Form DEF 14A - Other definitive proxy statements
08/12/202316:26EDGAR2Form PRE 14A - Other preliminary proxy statements
30/11/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202306:40EDGAR2Form 8-K - Current report
29/11/202306:30GLOBESAB Biotherapeutics Announces Commencement of the HUMAN..
28/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
28/11/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202315:45EDGAR2Form 8-K - Current report
20/11/202316:00EDGAR2Form 8-K - Current report
20/11/202315:45EDGAR2Form S-3/A - Registration statement under Securities Act of..
20/11/202306:30GLOBESAB Biotherapeutics Appoints Katie Ellias to the Board of..
14/11/202318:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202306:30GLOBESAB Biotherapeutics Announces Completion of $67.1 Million..
14/11/202306:15GLOBESAB Biotherapeutics Announces Q3 2023 Financial Results and..
13/11/202315:48EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202306:30GLOBESAB Biotherapeutics to Present at Piper Sandler Healthcare..
03/11/202316:00EDGAR2Form S-3 - Registration statement under Securities Act of..
03/11/202315:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/10/202316:00EDGAR2Form DEF 14A - Other definitive proxy statements
27/10/202316:00EDGAR2Form 8-K - Current report
24/10/202316:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202306:30GLOBESAB Biotherapeutics Appoints Michael G. King Jr. as Chief..
20/10/202315:30EDGAR2Form PRE 14A - Other preliminary proxy statements
19/10/202306:30GLOBESAB Biotherapeutics Receives Australian Approval to Commence..
05/10/202306:30GLOBESAB Biotherapeutics Approves Appointment of Andrew Moin to..
02/10/202315:10EDGAR2Form 8-K - Current report
02/10/202306:30GLOBESAB Biotherapeutics Announces Private Placement of up to..
21/8/202315:15EDGAR2Form S-3 - Registration statement under Securities Act of..
21/8/202307:30GLOBESAB Biotherapeutics Provides Company Update for Q2..
21/8/202307:25EDGAR2Form 8-K - Current report

Su Consulta Reciente

NASDAQ
SABS
SAB Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados